1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,395 | 6,685 | 12:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ... | 1 | HKEx | ||
| 09.12. | Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer | 230 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase... ► Artikel lesen | |
| 09.12. | HENLIUS Receives Approval for Clinical Trials of HLX22 and HLX87 Combination Therapy for Breast Cancer Treatment | 1 | AASTOCKS | ||
| 09.12. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATIONS FOR PHASE 2/3 CLINICAL TRIALS OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) ... | 1 | HKEx | ||
| 03.12. | HENLIUS (02696): PROXY FORM FOR THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING TO BE HELD ON 31 DECEMBER 2025 (OR ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 03.12. | HENLIUS (02696): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 03.12. | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 03.12. | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION | 1 | HKEx | ||
| 03.12. | HENLIUS (02696): CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS - COLLABORATION AGREEMENTS WITH AVANC PHARMA FOR FOVINACICLIB CITRATE CAPSULES | - | HKEx | ||
| 02.12. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY ... | 2 | HKEx | ||
| 01.12. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ... | - | HKEx | ||
| 25.11. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR ... | 1 | HKEx | ||
| 20.11. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT TREATMENT FOR GASTRIC ... | - | HKEx | ||
| 18.11. | Organon & Co.: Henlius und Organon geben die Zulassung von POHERDY (Pertuzumab-dpzb) durch die US-amerikanische Arzneimittelbehörde FDA bekannt, dem ersten PERJETA (Pertuzumab)-Biosimilar in den USA | 580 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) den Antrag auf Zulassung von... ► Artikel lesen | |
| 17.11. | Henlius and Organon score first US Perjeta biosimilar approval | 18 | Pharmaceutical Technology | ||
| 14.11. | Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod | 26 | FiercePharma | ||
| 14.11. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) APPROVED HLX11 (PERTUZUMAB-DPZB, TRADE NAME IN THE UNITED ... | - | HKEx | ||
| 10.11. | Henlius stands out in Hong Kong's cooling biotech market with profits and pipeline progress | 2 | KrASIA | ||
| 05.11. | XFRA NEW INSTRUMENTS AVAILABLE ON 05.11.2025 | 472 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.11.2025
Aktien
1 US05374V1089 Avio S.p.A. ADR
2 NO0003087603... ► Artikel lesen | |
| 17.10. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - ORPHAN-DRUG DESIGNATION OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ... | - | HKEx |
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,640 | 0,00 % | Immunome: Evercore ISI hebt Kursziel nach positiven Studiendaten auf 40 $ an | ||
| APOGEE THERAPEUTICS | 76,81 | 0,00 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| ADMA BIOLOGICS | 19,730 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DISC MEDICINE | 92,00 | +0,16 % | H.C. Wainwright reiterates Buy rating on Disc Medicine stock | ||
| VERA THERAPEUTICS | 49,170 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,300 | 0,00 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 19,010 | 0,00 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| RADIOPHARM THERANOSTICS | 10,630 | 0,00 % | Radiopharm (RADX) Sees Slight Pessimism From Analysts | ||
| KYVERNA THERAPEUTICS | 10,810 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 35,840 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| PRAXIS PRECISION MEDICINES | 276,42 | +2,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,080 | 0,00 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 40,230 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 85,62 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,430 Euro und damit -2,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.